Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Por:
Lluch A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz J, Torres R, de la Haba J, Garcia-Martinez E, Gomez H, Llombart A, Bofill J, Baena-Canada J, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernandez I, Rodriguez-Lescure A, Cardenas J, Vinholes J, de Duenas E, Godes M, Segui M, Anton A, Lopez-Alvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero M, Bezares S, Carrasco E, Martin M, Corona J, Jara C, Cardemil B, Toro R, Pimentel C, Hernando B, Vicente E, Zagame L, Gil M, Estevez L, Rodriguez C, de la Cruz M, Tello J, Campos S, Lomas M, Capdevile D, Campos M, Margeli M, Andres R, Tusquets I, Ballesteros A, Guerrero A, Arguello M, Rodriguez J, Munoz M, Florian J, Azevedo S, Mondragon R, Peralta J, Palomo A, Barajas L, Arcusa A, Carranza H, Garcia C, Umbria C, Ales J, Vega J, Romeo M, Valero J, Alonso J, Mathias C, Gutierrez F, Adrover E, Nunez P, Mendiola C, Cassinello J, de la Huerta A, Geicam Spanish Breast Canc Grp, CIBOMA Iberoamer Coalition Res Bre, LACOG
Publicada:
20 ene 2020
Resumen:
PURPOSE Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC.
PATIENTS AND METHODS Eligible patients were those with operable, node-positive-or node negative with tumor 1 cm or greater-TNBC, with prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to either capecitabine or observation. Stratification factors included institution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype (basal v nonbasal, according to cytokeratins 5/6 and/or epidermal growth factor receptor positivity by immunohistochemistry). The primary objective was to compare disease-free survival (DFS) between both arms.
RESULTS Eight hundred seventy-six patients were randomly assigned to capecitabine (n = 448) or observation (n = 428). Median age was 49 years, 55.9% were lymph node negative, 73.9% had a basal phenotype, and 67.5% received previous anthracyclines plus taxanes. Median length of follow-up was 7.3 years. DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82; 95% CI, 0.63 to 1.06; P = .136]. In a preplanned subgroup analysis, nonbasal patients seemed to derive benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those with basal phenotype (interaction test P = .0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype (interaction test P = .0052). Tolerance of capecitabine was as expected, with 75.2% of patients completing the planned 8 cycles.
CONCLUSION This study failed to show a statistically significant increase in DFS by adding extended capecitabine to standard chemotherapy in patients with early TNBC. In a preplanned subset analysis, patients with nonbasal phenotype seemed to obtain benefit with capecitabine, although this will require additional validation. (C) 2019 by American Society of Clinical Oncology
Filiaciones:
Lluch A:
Univ Valencia, Hosp Clin Univ Valencia, Valencia, Spain
Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain
Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Barrios C:
Ctr Pesquisa Clfn Hosp Sao Lucas PUCRS, Porto Alegre, RS, Brazil
LACOG, Porto Alegre, RS, Brazil
Torrecillas L:
Ctr Med Nacl 20 Noviembre, Inst Seguridad & Serv Sociales Trabajadores Estad, Ciudad De Mexico, Mexico
Ruiz-Borrego M:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Univ Virgen Rocio, Seville, Spain
Bines J:
LACOG, Porto Alegre, RS, Brazil
Inst Nacl Canc, Rio De Janeiro, Brazil
Segalla J:
LACOG, Porto Alegre, RS, Brazil
Hosp Amaral Carvalho, Sao Paulo, Brazil
Guerrero-Zotano A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Inst Valenciano Oncol, Valencia, Spain
Garcia-Saenz J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Clin San Carlos, Madrid, Spain
Torres R:
Inst Nacl Canc, Santiago, Chile
de la Haba J:
Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Univ Reina Sofia, Cordoba, Spain
Garcia-Martinez E:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Gen Univ Morales Meseguer, Murcia, Spain
Gomez H:
Inst Nacl Enfermedades Neoplas, Lima, Peru
Peruvian Oncol Clin Studies Grp, GECOPERU, Lima, Peru
Llombart A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Arnau Vilanova, Lleida, Spain
Bofill J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Univ NS Valme, Seville, Spain
Baena-Canada J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Univ Puerta Mar, Cadiz, Spain
Inst Invest & Innovac Biomed Cadiz, Cadiz, Spain
Barnadas A:
Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Univ Autonoma Barcelona, Inst Recerca Biomed St Pau, Med Dept, Hosp Santa Creu & St Pau, Barcelona, Spain
Calvo L:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Complexo Hosp Univ A Coruna, La Coruna, Spain
Perez-Michel L:
Hosp San Jose, Obregon, Sonora, Mexico
Ramos M:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Ctr Oncol Galicia, La Coruna, Spain
Fernandez I:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Complexo Hosp Univ Vigo, Vigo, Spain
Rodriguez-Lescure A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Gen Univ Elche, Alicante, Spain
Cardenas J:
Ctr Med Colima, Colima, Mexico
Vinholes J:
LACOG, Porto Alegre, RS, Brazil
Unidade Novos Tratamentos CliniOnco, Porto Alegre, RS, Brazil
de Duenas E:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain
Godes M:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Gen Univ Valencia, Valencia, Spain
Segui M:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Corporacio Sanitaria Parc Tauli Sabadell, Barcelona, Spain
Anton A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon, Zaragoza, Spain
Lopez-Alvarez P:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain
Moncayo J:
Social S Hosp Teodoro Maldonado Carbo, Guayaquil, Ecuador
Amorim G:
LACOG, Porto Alegre, RS, Brazil
Oncol DOr, Rio De Janeiro, Brazil
Villar E:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Reg Univ Carlos Haya, Malaga, Spain
Reyes S:
Hosp Beneficiencia Espanola, San Luis Potosi, Mexico
Sampaio C:
LACOG, Porto Alegre, RS, Brazil
Clin Amo Itaigara, Salvador, BA, Brazil
Cardemil B:
Hosp Base Valdivia, Valdivia, Chile
Escudero M:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Bezares S:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Carrasco E:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Martin M:
Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
Cardemil B:
Hosp Base Valdivia, Valdivia, Chile
|